<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364274">
  <stage>Registered</stage>
  <submitdate>18/05/2013</submitdate>
  <approvaldate>20/05/2013</approvaldate>
  <actrnumber>ACTRN12613000570785</actrnumber>
  <trial_identification>
    <studytitle>Determining the Effect of Abacavir on Platelet Activation in HIV positive men</studytitle>
    <scientifictitle>Determining the Effect in HIV positive men of Abacavir administration on markers of Platelet Activation</scientifictitle>
    <utrn>U1111-1143-2410</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV</healthcondition>
    <healthcondition>Cadiovascular disease</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Abacavir 600mg (2x 300mg oral tablets) daily for 15 days.
Adherence assessed by compliance questionaire and tablet return at day 15 visit</interventions>
    <comparator>No control</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in P-VASP assay</outcome>
      <timepoint>Day 15</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in novel markers of platelet activaiton (expression and shedding of platelet specific collagen receptor, GPVI)</outcome>
      <timepoint>day 15</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events (specifically hypersensitivity reactions - assessed clinically)</outcome>
      <timepoint>Day 15 and 43
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reversibility of the effects of abacavir on platelet function, as assessed by changes in P-VASP assay and sGPVI.</outcome>
      <timepoint>at day 43 compared with baseline and day 15
</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>HIV positive men with well controlled HIV (undetectable viral load for &gt; six months) on a non-abacavir containing antiretroviral regimen</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Previous allergy to abacavir or HLA*B*57*01 positivity
High Cardiovascular risk
Platelet disorder
Current or recent use of antiplatelets</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>This an open label single arm self-controlled interventional study</concealment>
    <sequence>N/A</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>N/A</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>The study is powered to demonstrate an effect of abacavir on platelet reactivity in HIV positive adult men. Conservatively assuming a mean 5% increase in platelet activation secondary to abacavir with a standard deviation of 5% (as was demonstrated by Satchell et.al.), we estimate that 23 participants are required to have an 80% power to detect a difference of one standard deviation in mean P-VASP between the baseline and day 15. </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/08/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/12/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>23</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Alfred Health</primarysponsorname>
    <primarysponsoraddress>Alfred Health
Commercial Rd, Melbourne VIC 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Prof Jennifer Hoy</fundingname>
      <fundingaddress>C/O Alfred Health
Infectious Diseases Department
Commercial Rd, Melbourne VIC 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>open label single arm self-controlled trial of the affect of 15 days of abacavir on platelet function in healthy HIV positive volounteers</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Health Ethics Commitee</ethicname>
      <ethicaddress>C/O Alfred Health
Human research and Ethics
Commercial Rd
Melbourne VIC 3004</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>27/05/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Janine Trevillyan</name>
      <address>C/O Alfred Health
Department of Infectious Diseases
Commercial Rd 
Melbourne VIC 3004</address>
      <phone>+61 419743720</phone>
      <fax />
      <email>janine.trevillyan@monash.edu</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Janine Trevillyan</name>
      <address>C/O Alfred Health
Department of Infectious Diseases
Commercial Rd 
Melbourne VIC 3004</address>
      <phone>+61 419743720</phone>
      <fax />
      <email>janine.trevillyan@monash.edu</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Janine Trevillyan</name>
      <address>C/O Alfred Health
Department of Infectious Diseases
Commercial Rd 
Melbourne VIC 3004</address>
      <phone>+61 419743720</phone>
      <fax />
      <email>janine.trevillyan@monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>